Search - tctmd.com

Displaying 1 - 20 of 102

Sort: Relevancy | Date

News Conference News AHA 2016

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

Shelley Wood

November 21, 2016

News Conference News AHA 2016

Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias

Shelley Wood

November 21, 2016

News Conference News AHA 2016

误诊 NOAC 在日常实践中很常见，并对中风和出血有影响

Shelley Wood

November 21, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

News Daily News

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Michael O'Riordan

October 11, 2016

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Industry News

St. Jude Medical Launches Global Clinical Trial to Evaluate a New Therapy Option for Patients at an Increased Risk of Stroke Due to Atrial Fibrillation

September 01, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

New-Onset A-Fib, Chronic Kidney Disease Are Risk Factors For Stroke After TAVR, Meta-Analysis Shows

Yael L. Maxwell

August 10, 2016

News Daily News

Evidence Supporting Percutaneous or Surgical LAA Exclusion for Stroke Prevention Is Limited, Review Says

Todd Neale

July 14, 2016

News Daily News

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

Michael O'Riordan

June 29, 2016

News Daily News

Black Individuals Have Less A-fib, but When They Do, the Consequences Are More Dire

Michael O'Riordan

June 24, 2016

News Daily News

Majority of FDA Advisors Give Green Light to Amplatzer PFO Closure Device for Stroke

Shelley Wood

May 25, 2016

News Conference News EuroPCR 2016

Embolic Protection in TAVR: If, When, What, and How Debated as Trials Wrap Up

Shelley Wood

May 20, 2016

Presentation EuroPCR 2016

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Presenter: Jens Erik Nielsen-Kudsk

May 20, 2016

News Daily News

Real-World Study Largely Confirms Effects of Apixaban, Rivaroxaban for A-fib

Todd Neale

April 21, 2016

News Industry News

Real-World Study Shows 72 Percent of Atrial Fibrillation Would Have Gone Undiagnosed in Stroke Patients if Cardiac Monitoring Had Been Limited to 30 Days

April 20, 2016

Advertisement

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias

误诊 NOAC 在日常实践中很常见，并对中风和出血有影响

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

St. Jude Medical Launches Global Clinical Trial to Evaluate a New Therapy Option for Patients at an Increased Risk of Stroke Due to Atrial Fibrillation

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

New-Onset A-Fib, Chronic Kidney Disease Are Risk Factors For Stroke After TAVR, Meta-Analysis Shows

Evidence Supporting Percutaneous or Surgical LAA Exclusion for Stroke Prevention Is Limited, Review Says

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

Black Individuals Have Less A-fib, but When They Do, the Consequences Are More Dire

Majority of FDA Advisors Give Green Light to Amplatzer PFO Closure Device for Stroke

Embolic Protection in TAVR: If, When, What, and How Debated as Trials Wrap Up

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Real-World Study Largely Confirms Effects of Apixaban, Rivaroxaban for A-fib

Real-World Study Shows 72 Percent of Atrial Fibrillation Would Have Gone Undiagnosed in Stroke Patients if Cardiac Monitoring Had Been Limited to 30 Days

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content